Novo Nordisk's drug Wegovy achieved significant success and valuation due to its high demand and need in the Western World. However, the company faced operational challenges in meeting the demand for the drug, leading to concerns about its production capacity and quality. Competitors are also anticipated to intensify their efforts to enhance their drugs, bolster their marketing strategies, offer competitive pricing, and potentially overshadow Novo Nordisk. These factors can significantly impact the market share and pricing of the drug, as stated by Graham Cookson, the chief executive of the Office of Health Economics. Moreover, the success of introducing a new and popular drug can create vulnerability for the manufacturer, particularly if it is a smaller or medium-sized company.